KPV (Lysine-Proline-Valine)

KPV is a chain of just three amino acids - lysine, proline and valine, whose one-letter codes spell K, P and V. It is the tail end of a larger hormone your body already makes called alpha-melanocyte-stimulating hormone, usually shortened to alpha-MSH, which is produced in the pituitary gland. Researchers became interested in this fragment because it appears to keep the anti-inflammatory behaviour of the full hormone while losing the part that darkens skin. Almost everything published about it comes from cell cultures and from mice, rats and rabbits. When the United States Food and Drug Administration reviewed KPV in May 2026 for the list of substances pharmacies may compound, it searched PubMed, Embase, ClinicalTrials.gov and its own adverse event database and reported that it found no clinical studies or human exposure data for KPV by any route of administration.

• Inflammatory bowel disease, colitis and general gut inflammation, which is where the largest body of animal work sits
• Wound healing and skin repair, the use the FDA was asked to evaluate, supported by rodent and rabbit models
• General anti-inflammatory use, based on cell work showing reduced nuclear factor kappa B signalling
• Antimicrobial claims against Staphylococcus aureus and Candida albicans, which come from culture-dish experiments
• Mast cell activation syndrome, histamine intolerance and similar conditions, which are marketing claims the FDA catalogued from vendor websites rather than findings from any study

Picture inflammation as a building alarm system where one master switch in the control room turns on every siren at once. That master switch is a protein called nuclear factor kappa B. In cell experiments KPV slips inside the cell, partly through a doorway called PepT1 that inflamed gut cells open wider than usual, and holds that master switch down so fewer sirens fire. The practical catch is that everything in this description was watched in a dish or in a rodent, and nobody has published what happens when a person takes it.

1. Before day 1There is no human timeline for KPV at all. No clinical study, no pharmacokinetic study and no dose-ranging work has been published for any route, so every schedule you see online is convention passed between clinics rather than evidence.
2. Day 1-7In the mouse colitis studies, oral KPV given alongside the colitis-inducing agent reduced weight loss and inflammatory markers over roughly the first week. That is a prevention design in rodents, not a treatment response measured in people.
3. Week 1-2The 2008 Inflammatory Bowel Diseases study reported earlier recovery and stronger regain of body weight in treated mice over this window. Rodents run colitis experiments on a compressed clock, so the timing does not transfer to a human gut.
4. Week 4-8This is the cycle length shown in the cheatsheet above, and it comes from practitioner convention. No published study has tested KPV for four to eight weeks in a person, so there is no evidence about what does or does not accumulate over that period.
5. Month 3+Nothing is known. The FDA review found no repeat-dose toxicity, genotoxicity, reproductive or carcinogenicity studies of KPV in animals, let alone long-term human follow-up.

• No adverse events were reported in the studies located, which is not the same as none existing - the FDA searched its Adverse Event Reporting System through 3 December 2025 and retrieved no reports at all, and a matching literature search found no case reports
• That silence is best read as absence of data rather than absence of harm, because there are no human studies to generate reports and compounders operating under section 503A generally do not report adverse events to the FDA
• The FDA flagged immunogenicity as an open risk: peptides can provoke antibody responses, and there was no information available to assess immunogenicity or aggregation for either KPV free base or KPV acetate
• The agency also found no acute toxicity, repeat-dose toxicity, genotoxicity, developmental and reproductive toxicity, or carcinogenicity studies for either form
• Product identity is a practical hazard here: the FDA noted that KPV is a common name rather than an official one, that suppliers list KPV acetate under the same chemical registry number as the free base, and that certificates of analysis it found typically report purity with no impurity, aggregate or microbiological limits

• You are pregnant, trying to conceive, or breastfeeding, since the FDA review found no developmental or reproductive toxicity studies of any kind
• You have a current or past cancer diagnosis, since no carcinogenicity study exists and the one tumour-related study located is a mouse model of colitis-associated cancer rather than a human safety assessment
• You have an autoimmune condition or take immune-modulating medicine, because KPV is described throughout the literature as suppressing inflammatory signalling and nobody has measured what that does on top of existing treatment
• You have active inflammatory bowel disease and would be using this instead of treatment that has been tested, as the FDA specifically noted that approved therapies with established efficacy already exist for wounds and for inflammatory diseases
• You are not working with a physician who knows what you are taking, which matters more than usual for a substance with no human data at all

• Treating the melanocortin-receptor story as settled. The FDA review summarised in-vitro work in which KPV failed to displace alpha-MSH binding in rat brain, murine melanoma cells and MC1 receptor-expressing macrophages, and did not raise cyclic AMP in those macrophages, so the receptor it is named after is probably not its target
• Over-concentrating the vial. KPV free base is reported soluble in water only up to about 0.7 mg per millilitre, so 10 mg into 2 mL sits well above that figure and can leave undissolved peptide; reconstitution volume is worth discussing with whoever supplied it
• Storing it like a small molecule. Lyophilised powder is reported stable for around three years at minus 20 degrees Celsius but only about three months at 15 degrees, and reconstituted solution keeps for roughly a week at 10 degrees, so warm shelves and slow shipping matter
• Expecting a cream to work like an injection. An in-vitro study on human cadaver skin found KPV permeation below detectable levels by passive diffusion, and only iontophoresis plus microneedle micropores moved meaningful amounts through the outer skin layer
• Assuming a compounding-committee vote means the substance was shown to work. The FDA's own review concluded the criteria weighed against listing KPV, and the advisory committee's recommendation is non-binding advice, not an efficacy finding